ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 92 filers reported holding ASCENDIS PHARMA A/S in Q1 2018. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $3,141,000 | +10.3% | 30,416 | -0.7% | 0.03% | +7.1% |
Q2 2022 | $2,847,000 | -65.7% | 30,630 | -56.5% | 0.03% | -52.5% |
Q1 2019 | $8,294,000 | +36.3% | 70,468 | -27.5% | 0.06% | +25.5% |
Q4 2018 | $6,086,000 | +31.2% | 97,135 | +48.4% | 0.05% | +56.7% |
Q3 2018 | $4,638,000 | +30.8% | 65,448 | +22.7% | 0.03% | +30.4% |
Q2 2018 | $3,547,000 | +11.2% | 53,324 | +9.3% | 0.02% | -8.0% |
Q1 2018 | $3,190,000 | +97.6% | 48,775 | +21.0% | 0.02% | +127.3% |
Q4 2017 | $1,614,000 | +39.5% | 40,297 | +26.2% | 0.01% | +37.5% |
Q3 2017 | $1,157,000 | +42.5% | 31,929 | +9.1% | 0.01% | +33.3% |
Q2 2017 | $812,000 | +7.0% | 29,264 | +7.9% | 0.01% | +20.0% |
Q1 2017 | $759,000 | +23.8% | 27,120 | -10.5% | 0.01% | 0.0% |
Q4 2016 | $613,000 | +17.0% | 30,296 | +7.2% | 0.01% | 0.0% |
Q1 2016 | $524,000 | -13.5% | 28,259 | -14.6% | 0.01% | -16.7% |
Q4 2015 | $606,000 | -90.8% | 33,102 | -11.3% | 0.01% | -14.3% |
Q3 2015 | $6,604,000 | +1491.3% | 37,310 | +57.9% | 0.01% | +75.0% |
Q2 2015 | $415,000 | – | 23,626 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |